THE SYNDROME OF PREECLAMPSIA
============================

Preeclampsia affects 3--5% of all pregnancies. The traditional definition of preeclampsia as *de novo* onset of hypertension and proteinuria after 20 weeks of gestation has been recently modified by the American College of Obstetricians and Gynecologists in recognition of the syndromic nature of preeclampsia. In the absence of proteinuria, preeclampsia is diagnosed as hypertension in association with thrombocytopenia, impaired liver function, new development of renal insufficiency, pulmonary edema, or new-onset cerebral or visual disturbances (American College of Obstetricians Gynecologists \[ACOG\], 2013). Hypertension, proteinuria, edema, and other systemic manifestations of the syndrome of preeclampsia are the direct consequences of maternal endothelial dysfunction. The syndrome is a major cause of maternal and fetal morbidity and mortality, and results in mild to severe microangiopathy of target organs, including the brain, liver, kidney, and placenta ([@B116]). Severe maternal complications include seizures (eclampsia), stroke, renal failure, liver failure, and/or rupture, HELLP syndrome (hemolysis, elevated liver enzymes, and low platelets), and death ([@B134]). Fetal complications include prematurity due to preterm delivery, fetal growth restriction, fetal/neonatal hypoxic neurological injury, perinatal death, and long-term cardiovascular morbidity associated with low birth weight ([@B116]).

Preeclampsia (PE) is a complex multifactorial disease; many factors, including genetic predisposition, immunological interactions, maternal endothelial function and environmental factors interact and culminate in the disease manifestation. In recent years, PE is commonly subdivided into early and late-onset, as the two conditions seem to have different underlying etiologies. Both early and late onset diseases present with abnormal placental perfusion and oxidative stress, however, poor placentation and deficient conversion of maternal spiral arteries only underlie the pathology of the early onset disease, whilst the late onset condition is associated with normal uterine spiral artery conversion and normally grown baby ([@B59]). Redman recently proposed a novel hypothesis for the pathology of late-onset PE, suggesting an intrinsic cause due to microvillous overcrowding, as placental growth reaches its functional limit. In both conditions, oxidatively stressed syncytiotrophoblast over-secrets proteins that perturb maternal angiogenic balance ([@B104]). Abnormal placentation is recognized as a main prerequisite for the pathogenesis of early onset preeclampsia. The disease seems to progress in two stages; in stage I (preclinical), poor development of the early placenta leads to deficient remodeling of maternal spiral arteries and consequent ischemia-reperfusion type injury of the placenta and oxidative stress. In stage II (clinical), the ischemic/malperfused placenta triggers the secretion of a mixture of placental factors, including antiangiogenic factors, proinflammatory cytokines and apoptotic debris that culminate in an enhanced maternal inflammatory response and in turn induce systemic endothelial dysfunction and the maternal syndrome of preeclampsia ([@B106]; [@B103]).

In conditions of PE and IUGR which result in fetal hypoxia, there is a tendency to refer to fetoplacental hypoxia as the underlying cause. This concept has been challenged by several groups who advocate caution when interpreting results from pregnancies complicated by PE and IUGR ([@B71]; [@B82]; [@B60]). These studies suggest that late-onset PE and late onset IUGR with present end diastolic flow (EDF) are associated with ischemic uteroplacental hypoxia in which the delivery of blood to the intervillous space is compromised due to deficient trophoblast invasion. This placental malperfusion results in ischemia-reperfusion injury affecting trophoblast and vascular endothelium, however fetal extraction of O~2~ is not compromised and there is evidence of increased placental branching angiogenesis ([@B82]). In contrast, pregnancies complicated by early onset PE, which is usually accompanied with early onset IUGR with absent/reversed EDF are often referred to as 'placental hyperoxia' due to compromised fetoplacental blood flow which fails to extract oxygen from the intervillous space, leading to poor fetal oxygenation and higher than normal intervillous oxygen levels (postplacental hypoxia; [@B71]; [@B82]).

Medical intervention in preeclampsia remains limited, centering on management of maternal hypertension and systemic complications, seizure prevention with magnesium sulfate, and delivering the fetus before term as a measure of treating maternal effects and preventing further growth restriction. However, any benefits this confers are offset by the complications of prematurity. Hence, identifying interventions that would modulate the pathological processes involved in the disease pathogenesis are key to intervening effectively in preeclampsia to improve maternal and fetal prognosis. This review will focus on the role of angiogenic and antiangiogenic factors in mediating maternal endothelial dysfunction and explore some therapeutic strategies aimed at targeting these factors in order to reverse/ameliorate the disease pathology.

EVIDENCE FOR THE ROLE OF ANGIOGENIC FACTORS IN PREECLAMPSIA
===========================================================

Placental vasculature is plastic and changes constantly throughout pregnancy to facilitate the rapid growth, and supply the increasing metabolic needs of the growing fetus ([@B24]). Normal placental development is regulated by proangiogenic and antiangiogenic factors. The processes of vasculogenesis, *de novo* formation of blood vessels from precursor cells, and angiogenesis, creation of vessels from pre-existing vessels, are critical in the fetal and placental development for effective transport of oxygen, nutrients and fetal growth and development ([@B24]). In contrast, angiogenesis is a rare event in adult vascular networks under physiological conditions, being limited to organs of the female reproductive tract (endometrium, ovary, placenta). Appearance of new blood vessel growth in other organs is regarded as pathological, and can be involved in conditions such as wound healing, tumor growth, and retinopathy.

Placental abnormalities lead to secretion of a mixture of proteins that stimulate maternal endothelium and result in the disease presentation. Recently, circulating antiangiogenic proteins, soluble vascular endothelial growth factor receptor 1 \[VEGF-R1, also referred to as soluble fms-like tyrosine kinase (sFlt1)\] and soluble TGF-β co-receptor endoglin (sEng), have been implicated in the pathogenesis of many of the maternal features of preeclampsia. We will first consider the role of proangiogenic factors, VEGF and transforming growth factor (TGF-β), and their receptors in vascular homeostasis (**Table [1](#T1){ref-type="table"}**). VEGFs are a family of secreted dimeric glycoproteins involved in vasculogenesis and angiogenesis. In humans and other mammals, VEGF-A (referred here as VEGF) and its placental homologue placental growth factor (PlGF) are the most important members with proangiogenic activity ([@B69]; [@B78]; [@B81]). VEGF promotes survival and proliferation of endothelial cells and induces vascular permeability ([@B69]; [@B78]). Two VEGF receptors, VEGF-R1 (Flt-1) and VEGF-R2 (Flk-1/KDR) are present on endothelial cells. VEGF binds to both receptors whilst PlGF homodimers bind exclusively to VEGF-R1. VEGF-R2 it thought to primarily mediate the actions of VEGF on endothelial cells. The function of VEGF-R1 is less well defined, although it is thought to modulate VEGF-R2 signaling. Another function of VEGF-R1 is to act as a decoy receptor (sFlt-1), sequestering VEGF from VEGF-R2 binding (**Table [1](#T1){ref-type="table"}**; [@B96]; [@B126]; [@B70]). TGF-β is another important molecule involved in angiogenesis, it has been implicated in the development of the vasculature ([@B94]). TGF-β signals via binding to both type I (ALK1 and ALK5) and type II receptors. In addition, TGF-β signaling in the vasculature involves coreceptors that act to modulate its effects. Endoglin (CD105) is a TGF-β coreceptor expressed by endothelial cells and placental syncytiotrophoblast. TGF-β effects *in vitro* seem concentration-dependent, inducing proliferation and migration of endothelial cells at low doses (ALK1 mediated), and inhibiting proliferation and migration of endothelial cells at high doses (via ALK5; [@B49]). In addition, TGF-β is an important modulator of VEGF signaling, further linking TGF-β to angiogenesis (**Table [1](#T1){ref-type="table"}**; [@B115]).

###### 

A brief description of function of angiogenic and antiangiogenic growth factors and their receptors in pregnancy.

  Molecules                                      Function and changes in pathological conditions
  ---------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  VEGF-A                                         Potent angiogenic protein and trophic cytokine essential for endothelial integrity
                                                 Free VEGF concentration decreased in preeclamptic women at disease presentation and even before the onset of disease ([@B83]; [@B120]; [@B80])
  PlGF                                           Key molecule in angiogenesis and vasculogenesis, in particular during embryogenesis. The main source of PlGF during pregnancy is the placental trophoblast
                                                 Reduced in maternal plasma in preeclampsia ([@B83]; [@B120]; [@B80])
  TGF-β                                          Important molecule involved in angiogenesis, it has been implicated in the development of the vasculature ([@B94]). *In vitro* effects are concentration-dependent, inducing proliferation and migration of endothelial cells at low doses (ALK1 mediated), and inhibiting proliferation and migration of endothelial cells at high doses (via ALK5; [@B49]). Important modulator of VEGF signaling, further linking TGF-β to angiogenesis ([@B115])
                                                 
  **Receptors**                                  
  VEGF-R1 (Flt-1)                                All members of the VEGF family stimulate cellular responses by binding to tyrosine kinase receptors (the VEGF-Rs) on the cell surface, causing them to dimerize and become activated through transphosphorylation
  VEGF-R2 (Flk-1)                                VEGF-A binds to VEGF-R1 (Flt-1) and VEGF-R2 (KDR/Flk-1), whilst PlGF only binds to VEGF-R1. VEGF-R2 appears to mediate almost all of the known cellular responses to VEGF. The function of VEGF-R1 is less well defined, although it is thought to modulate VEGF-R2 signaling. Another function of VEGFR-1 is to act as a decoy receptor (sFlt-1), sequestering VEGF from VEGF-R2 binding ([@B96]; [@B126]; [@B70])
  TGF-β RI (ALK1,5) TGF-β RII Endoglin (CD105)   TGF-β signals via binding to both type I (ALK1 and ALK5) and type II receptors. In addition, TGF-β signaling in the vasculature involves coreceptors, e.g., endoglin (CD105), that act to modulate its effects. Endoglin is a membrane glycoprotein expressed by endothelial cells and placental syncytiotrophoblast. It has a crucial role in angiogenesis, therefore, making it an important protein for tumor growth, survival and metastasis of cancer cells to other locations in the body ([@B49]; [@B115]).
                                                 
  **Antiangiogenic**                             **Factors**
                                                 
  sFlt-1                                         Formed by alternative splicing of the pre-mRNA encoding VEGF-R1. It can bind circulating VEGF and PlGF as it lacks the cytoplasmic and transmembrane domain, thus preventing their interactions with endogenous receptors. Increased in maternal plasma in preeclampsia ([@B120]; [@B80],[@B9]; [@B23]; [@B118])
  sEng                                           Reduces endothelial tube formation in vitro and leads to increased capillary permeability. It blocks TGF-β 1-induced vasodilation through interference of TGF-β 1 binding to its receptor ([@B124]). sEng is elevated in the sera of preeclamptic women, its circulating levels increase markedly beginning 2--3 months before the onset of preeclampsia, concentrations correlating with disease severity ([@B79])

The vascular endothelium relies on proangiogenic factors. Release of placentally derived antiangiogenic factors into maternal circulation is thus likely to cause angiogenic factor imbalance, leading to endothelial dysfunction that manifests as the symptoms of preeclampsia. Two such factors, sFlt-1 and sEng, have been implicated in the pathophysiology of preeclampsia (**Table [1](#T1){ref-type="table"}**). Soluble Flt-1 is formed by alternative splicing of the pre-mRNA encoding VEGF-R1. It can bind circulating VEGF and PlGF as it lacks the cytoplasmic and transmembrane domain, thus preventing their interactions with endogenous receptors. Soluble endoglin receptor sEng reduces endothelial tube formation *in vitro* and leads to increased capillary permeability. It blocks TGF-β1-induced vasodilation through interference of TGF-β1 binding to its receptor, this effect is likely to involve NO ([@B124]).

Let us now consider the clinical and experimental evidence for the role of angiogenic factor imbalance in the pathophysiology of preeclampsia. The circulating levels of two placental-derived antiangiogenic factors, sFlt-1 and sEng, are elevated in the circulation of women with preeclampsia, and may begin to rise even before the onset of clinical symptoms, whereas the circulating concentrations of VEGF and PlGF are reduced in preeclamptic women at disease presentation and even before the onset of clinical symptoms ([@B120]; [@B80], [@B79]; [@B23]; [@B118]). The levels of circulating sFlt-1 increase and PlGF decrease during the last two months of pregnancy in normotensive women, however, these changes are significantly more pronounced in women who later develop preeclampsia and occur on average about 5 weeks before the onset of the disease ([@B80]). sEng is elevated in the sera of preeclamptic women, its circulating levels increase markedly beginning 2--3 months before the onset of preeclampsia, concentrations correlating with disease severity ([@B79]). However, it should be noted that despite the strong evidence linking angiogenic factor imbalance with PE, not all preeclamptic patients present with increased sFlt-1 and decreased VEGF/PlGF levels, and other mechanisms such as inflammation, oxidative stress, immunological interactions, maternal endothelial function, etc. also play an important role in the pathophysiology of this multifactorial disease.

Animal studies provide strong evidence linking sFlt-1 to the pathogenesis of preeclampsia. Although animal models do not develop preeclampsia, exogenous administration of sFlt-1 to pregnant rats induces some of the symptoms similar to the preeclamptic phenotype, including hypertension, proteinuria, and glomerular endotheliosis ([@B83]). Similarly, glomerular endotheliosis and proteinuria can be induced in non-pregnant mice using antibodies against VEGF ([@B119]), or by reducing glomerular VEGF levels by 50% ([@B40]). In addition, administration of sFlt-1 can block VEGF and PlGF-induced microvascular relaxation of rat renal arterioles *in vitro* ([@B83]). These studies all demonstrate that abnormal inhibition of endogenous VEGF activity can induce maternal preeclampsia-like symptoms. Similarly, administration of a therapeutic VEGF neutralizing antibody leads to renal pathology which can be replicated in adult animals by conditional gene targeting ([@B39]). sFlt-treated animals do not develop additional symptoms of PE such as hemolysis and thrombocytopenia, seen in the HELLP syndrome. However, co-administration of sFlt-1 with sEng amplifies the symptoms, resulting in severe PE and/or HELLP syndrome, suggesting that these two placenta-derived factors could act in concert to induce severe preeclampsia ([@B124]). We have shown similar synergistic effects between sFlt-1 and TNF-α. sFlt-1 sensitized endothelial cells to pro-inflammatory factors, increasing endothelial cell activation, as measured by increases in endothelial intercellular adhesion molecule 1 (ICAM1), vascular cell adhesion molecule 1, endothelin 1 (ET-1), von Willebrand factor and leukocyte adhesion, and led to reduction of AKT Ser^473^ and endothelial nitric oxide synthase (eNOS) Ser^1177^ phosphorylation ([@B27]). The survival of endothelial cells *in vivo* under non-pathological conditions is critically dependent on autocrine VEGF signaling. Endothelial specific ablation of VEGF results in progressive endothelial degeneration and sudden death of mutant animals ([@B76]), whilst autocrine VEGF is necessary for the survival of hematopoietic stem cells ([@B45]), demonstrating that paracrine actions of VEGF are not sufficient to maintain the target cells. Thus, in preeclampsia the elevated circulating sFlt-1 is able to act in a dominant-negative fashion at the endothelial cell surface, blocking these autocrine signals ([@B27]).

LINKING ANTIANGIOGENIC FACTORS WITH ENDOTHELIAL DYSFUNCTION
===========================================================

Maternal symptoms of preeclampsia present as a consequence of maternal endothelial cell dysfunction, not due to dysregulation of maternal angiogenesis. Secretion of antiangiogenic factors from the placenta can adversely affect maternal endothelial function. The higher relative concentrations of the antiangiogenic factors are thought to potentiate vascular endothelial cell injury in the liver, kidney, brain, and the placenta itself, and thus trigger the symptoms of preeclampsia. Placental oxidative stress due to malperfusion is now commonly considered as the underlying source for antiangiogenic factors which are at the root of the symptomatic phase of preeclampsia. However, the mechanism linking the angiogenic imbalance with endothelial dysfunction is still under investigation. Endothelin-1 (ET-1), a potent vasoconstrictor and pressor agent involved in the regulation of blood pressure, has been shown to play a crucial role in the development of hypertension in experimental animal models of placental hypoxia/ischemia ([@B44]). Long-term infusion of ET-1 into sheep also induced preeclampsia-like symptoms, i.e., hypertension, proteinuria, and decreased uteroplacental blood flow ([@B50]). In addition, several studies have reported elevated levels of plasma ET-1 in preeclamptic pregnant women, compared to controls ([@B121]; [@B93]; [@B9]).

The expression of VEGF and sFlt-1 can be regulated by the hypoxia-inducible factor-1 (HIF-1), a key component of a widely operative transcriptional response activated by hypoxia. Hypoxia increases HIF-1α stability, but it can also be up-regulated under non-hypoxic conditions by inflammatory cytokines or microtubule-depolymerising agents involving the NF-κB pathway ([@B68]). HIF-1-mediated sFlt-1 secretion can by induced in placental explants by hypoxia or hypoxia-reoxygenation (HR) *in vitro* ([@B3]; [@B92]; [@B29]; [@B33]; [@B26]). These *in vitro* effects can be blocked by anti-oxidant vitamins, inhibitors of the p38 MAPK and NF-κB pathways, and by overexpression of the heme oxygenase (HO-1)/CO, suggesting the involvement of oxidative stress, NF-κB, p38 signaling and HO-1 in sFlt-1 and HIF-1α regulation ([@B26]). sEng inhibits TGF-β signaling in the vasculature, which includes effects on activation of eNOS and vasodilation. It has been postulated that increased circulating levels of sFlt-1 lead to reduction of VEGF and NOS, thus reducing NO production. Administration of sFlt-1 to pregnant rats induced hypertension and significantly increased the production of prepro-ET message levels in the renal cortex. The hypertensive response could be abolished with coadministration of an ET~A~ antagonist ([@B89]). Administration of sFlt-1 to pregnant animals thus impairs VEGF-R2-mediated NO production, reducing NO bioavailability, thereby increasing systemic peripheral resistance and inducing hypertension. NO bioavailability may be further reduced by increased oxidative stress, and leads to enhanced ET-1 production and increased blood pressure ([@B44]).

Differences have been reported in the oxygen sensing ability of early vs. late onset PE. [@B107] reported a disruption of oxygen sensing in early onset disease but not in the late-onset, and they speculate this contributes to decreased HIF-1α hydroxylation and breakdown, leading to its accumulation in early onset PE ([@B107]). As mentioned previously, hypoxia is disputed by many as the leading cause of placental pathologies. Instead, ischemia-reperfusion ([@B58]; [@B19]) or hyperoxia ([@B71]; [@B60]) have been proposed as the underlying etiological factors in PE. Nevertheless, all these conditions lead to generation of reactive oxygen species (ROS), which can increase HIF-1α levels and stability. In addition, HIF-1α can be stabilized under normoxic conditions by other mechanisms such as components of the immune system, especially inflammatory cytokines, and hormones ([@B140]). Preeclampsia is a condition of excessive inflammatory responses mediated by syncytiotrophoblast microparticles, pathogens and DAMPs (damage-associated molecular pattern), which activate toll-like receptors (TLR) and through binding to immune cells promote persistent inflammatory conditions in this syndrome ([@B75]). TNF-α can promote the release of sFlt-1 ([@B97]), and similarly, AT1 autoantibodies can promote the secretion of sEng and sFlt-1 through TNF-α-mediated mechanisms ([@B139]; [@B61]).

OXIDATIVE STRESS AND ANTIOXIDANTS
=================================

Strong evidence exists that generation of placental oxidative stress is a key intermediary event in the pathology of preeclampsia ([@B57]; [@B102]; [@B18]). It is thought that deficient conversion of the uterine spiral arteries and subsequent impaired perfusion of the placenta provides the initiating insult ([@B16]). In early gestation of normal pregnancy, the spiral arteries undergo substantial remodeling by invasive extravillous trophoblasts, which penetrate into the myometrium and convert muscular spiral arteries into flaccid tubes with no muscularis or elastic lamina, capable of supplying the hugely expanded blood flow of the third trimester placenta. In contrast, the remodeling is minimal in PE, only affecting the decidual segments of the spiral arteries, which retain their high-resistance ([@B16]). Maternal blood thus enters the intervillous space at a higher pressure and a faster rate, in a pulsatile jet-like manner, exposing placental villi to fluctuating oxygen concentrations, which contributes to the ischemia-reperfusion (I/R) type injury of the placenta ([@B64], [@B63]; [@B17]). The resulting oxidative stress is thought to induce the placenta to release a mixture of factors, including inflammatory cytokines, antiangiogenic factors, and apoptotic debris, which culminates in an enhanced maternal inflammatory response and endothelial dysfunction ([@B105]; [@B103]).

The role of oxidative stress in mediating PE pathophysiology is supported by reports of significantly decreased levels of antioxidant vitamins C, A, E, β-carotene, glutathione levels, and iron-binding capacity in the maternal circulation of women with preeclampsia. There is also evidence of diminished superoxide dismutase (SOD) levels and activity in the maternal and placental compartments of preeclamptic women, indicative of decreased total antioxidant protective capacity in preeclampsia ([@B125]). In the experimental model of reduced uterine perfusion pressure (RUPP) of placental ischemia-induced hypertension, treatment with vitamins C and E did not decrease blood pressure, while the SOD mimetic Tempol attenuated RUPP hypertension. Interestingly, treatment with an NADP(H) oxidase inhibitor attenuated but did not normalize hypertension, suggesting other ROS-generating pathways ([@B47]; [@B113]). Challenging placental explants with hypoxia-reoxygenation (HR) or hypoxia *in vitro* induced sFlt-1 expression via HIF-1α upregulation ([@B4]; [@B92]; [@B29]). We showed that administration of vitamins C and E can block HR-mediated sFlt-1 secretion, via inhibition of p38 and NF-κB signaling pathways ([@B29]; [@B26]). Similarly, the *in vivo* challenge of labor results in increased oxidative stress, and increased expression of HIF-1 α, sFlt-1 and VEGF ([@B29]).

The regulatory role of oxidative stress in the I/R-type injury in preeclampsia and cardiovascular disease, together with encouraging *in vitro* and *ex vivo* data introduced the hypothesis that antioxidant vitamins might play an important role in the treatment of the ischemic disease pathology. However, despite encouraging *in vitro* data and cohort trials, clinical trials aimed to treat women at risk of preeclampsia with vitamins C and E ([@B99]; [@B108]) showed no reduction in the incidence of the disease. These results are disappointing. Periconceptional use of vitamins in women is associated with lower rates of severe preterm births and extreme SGA, which seems to suggest that vitamin use might be effective during conception and early pregnancy ([@B22]), and that the clinical trial administration of vitamins occurred too late in pregnancy to reverse already established disease pathology. The outcome could also be affected by the composition of natural vs. synthetic vitamins, as evidence exists that healthy Mediterranean diet lowers the incidence of preterm birth ([@B52]) and coronary heart disease ([@B7]). Synergy between different mediators may also be important in disease treatment. Recent clinical trial found that whilst antioxidant vitamins alone did not have a protective effect for prevention of PE, there was a synergistic effect between [L]{.smallcaps}-arginine and vitamin C, reducing the incidence of PE in these patients ([@B122]). Endogenous NADPH oxidase and manganese SOD are required to maintain VEGF signaling and vascular homeostasis ([@B2], [@B1]). Interestingly, despite no effect of the vitamin trials on lowering the incidence of preeclampsia, antioxidant supplementation led to a significant decrease in the plasma concentration of sFlt-1 and an increase in the plasma concentration of PlGF ([@B100]), matching our *in vitro* findings and confirming the beneficial effect of antioxidants on VEGF signaling. Antioxidant vitamins could interfere with the normal physiological roles of VEGF and there seems to be a scope for potential use of antioxidants in preventing or ameliorating preeclampsia.

NO SUPPLEMENTATION
==================

Endothelium plays a crucial role in regulating vascular tone. In preeclamptic patients, endothelial activation is manifested by increased expression of markers of endothelial activation, including VCAM, endothelin, von Willebrand Factor, and thrombomodulin ([@B91]). Nitric oxide (NO), hydrogen sulfide (H~2~S), and carbon monoxide (CO) are three gaseous vasodilators that maintain the vascular tone. NO release from endothelial cells counter-balances the vasoconstriction produced by the sympathetic nervous system and the renin--angiotensin system. In addition, NO exerts many vasoprotective and anti-atherosclerotic properties, including protection from thrombosis, reduction of adhesion molecule expression and leukocyte adhesion. NO is produced by nitric oxide synthase (NOS), using [L]{.smallcaps}-arginine as a substrate. In addition, endogenously produced methylated amino acids such as asymmetric dimethylarginine (ADMA) can act as competitive inhibitors, and their secretion is increased in patients with cardiovascular disease and renal failure ([@B112]), as well as in women with high resistance placental circulation at risk of preeclampsia, IUGR, or both ([@B111]).

NO formation was found to be impaired in women with preeclampsia and gestational hypertension, compared to healthy pregnant controls. A negative correlation exists between plasma nitrite levels and sFlt-1 and sEng, suggesting an inhibitory effect of the angiogenic factors on NO formation ([@B110]). Given the important role of NO in the pathophysiology of preeclampsia, much research has concentrated on targeting the NO pathway as a potential therapy for preeclampsia. These include organic nitrates and *S*-nitrosothiols (e.g., *S*-nitrosoglutathione), [L]{.smallcaps}-arginine, inhibitors of cGMP breakdown (e.g., sildenafil), and other novel inhibitors of NO donor metabolism. This topic has been reviewed extensively by [@B65]. *S*-nitroglutathione (GSNO), endogenous *S*-nitrosothiol found ubiquitously in tissue, has been infused in women with preeclampsia and it has been shown to target not only the endothelial dysfunction, but also reduce platelet aggregation and activation, reduce sEng, and improve utero-placental perfusion with no adverse side effects, making it a good potential candidate for PE therapy ([@B35]; [@B77]; [@B65]). The effects of supplementation with NO precursor, [L]{.smallcaps}-arginine, have been studied in several clinical trials. A recent randomized control trial of high risk pregnant women showed that dietary supplementation with a combination of [L]{.smallcaps}-arginine and antioxidants was associated with a significant reduction in the incidence of preeclampsia, compared to antioxidants alone or placebo prevention of preeclampsia ([@B122]). These are encouraging results although they have to be interpreted with caution, given that the effects of [L]{.smallcaps}-arginine alone were not studied, and as such it is difficult to dissect out the relative contributions of [L]{.smallcaps}-arginine and antioxidants in reducing the incidence of the disease. These encouraging results were echoed in a recent systematic review of randomized trials focused on the role of [L]{.smallcaps}-arginine in the prevention of preeclampsia ([@B37]). The authors analyzed 7 randomized controlled trials testing the effects of [L]{.smallcaps}-arginine in pregnant women, and they reported [L]{.smallcaps}-arginine supplementation was associated with a significant reduction in the risk of preeclampsia in pregnant women with either established hypertension or who were considered at risk of preeclampsia ([@B37]).

The mechanism of the beneficial effect of [L]{.smallcaps}-arginine supplementation has been studied in pregnant rats in whom preeclampsia-like phenotype was induced with sFlt-1 administration ([@B90]). sFlt-1 infusion into pregnant rats induced hypertension associated with reductions in circulating levels of VEGF, significant proteinuria, and endothelial dysfunction, as marked by a 3.5% increase in renal cortical pro-ET mRNA expression ([@B84]; [@B46]; [@B89], [@B90]). Administration of [L]{.smallcaps}-arginine decreased sFlt-1 hypertension but had no effect on the blood pressure response in non-pregnant rats. In addition, [L]{.smallcaps}-arginine abolished the sFlt-mediated expression of renal cortical prepro-ET, suggesting that a reduction in NO synthesis may play an important role in the enhanced ET-1 production in response to sFlt-1 hypertension in pregnant rats ([@B90]). These data are supported by previous studies, which showed a link between reduced NO production and enhanced ET-1 production ([@B73]; [@B38]). It has been postulated that increased circulating levels of sFlt-1 lead to reduction of VEGF and NOS, thus reducing NO production ([@B44]).

ER STRESS AND ER STRESS INHIBITORS
==================================

Endoplasmic reticulum (ER) processes all secreted proteins, facilitating folding and post-translational modifications. Accumulation of misfolded proteins leads to activation of ER stress response pathways, collectively known as the Unfolded Protein Response (UPR). The aim of the UPR is to restore homeostasis by inhibiting translation of non-essential proteins, increasing the capacity of the chaperone and folding machinery, and stimulating degradation of misfolded proteins. Failure of the mechanism results in activation of apoptotic pathways. ER stress is a major regulator of cell homeostasis ([@B130]; [@B34]; [@B133]). The UPR is initiated by three transmembrane sensors normally held inactive by binding of the principal ER chaperone, GRP78. These sensors are PERK (PRKR-like ER kinase) that phosphorylates eukaryotic initiation factor 2α (eIF2α) to inhibit translation, ATF6 (activating transcription factor 6) and IRE1 (inositol-requiring enzyme 1). ATF6 is cleaved to produce an active transcription factor, while IRE1 splices the mRNA encoding XBP-1 (X-box binding protein-1) to produce a second transcription factor. These factors have overlapping functions, and both upregulate ER chaperone proteins, including GRP78, and degradation pathways ([@B130]; [@B34]; [@B133]). In addition, ER stress can generate and accumulate ROS, thus promoting oxidative stress. Activation of the NF-κB pathway links increased oxidative stress, ER stress and inflammation. NF-κB can be activated by an increase in ER stress via PERK-eIF2α activation or IRE1α autophosphorylation. This effect can be blocked by both calcium chelators and antioxidants, suggesting NF-κB activation could be a result of the oxidative stress arising from excessive protein folding and/or ER-stress mediated Ca^2+^ leakage ([@B137]).

Disorders of ER function are recognized to underlie many diverse pathologies, including diabetes and neurodegenerative diseases, and therapeutic interventions targeting it are being devised ([@B53]). ER stress also seems instrumental in the pathophysiology of preeclampsia and IUGR ([@B135], [@B136]). Use of ER chaperones proved a beneficial therapy for treatment of type 2 diabetes as it restored systemic insulin sensitivity, normalized hyperglycemia, resolved fatty liver disease, and enhanced insulin action in various tissues ([@B95]). Similarities exist between preeclampsia and metabolic syndrome, including dyslipidemia, inflammation, insulin resistance, oxidative stress and ER stress. We have demonstrated an increased expression of ET-1 and sFlt-1 in HR-treated placental explants ([@B29]; [@B26]). Conditioned medium from HR explants induced ER stress in JEG-3 cells, which was abolished by an ET-1 neutralizing antibody ([@B62]). Administration of ER chaperone TUDCA to placental explants challenged with HR reduced the levels of endothelin-1 (ET-1) in these explants, and it reduced the protein levels of sFlt-1 (unpublished observations). These data suggest that restoring ER function could also offer a therapeutic benefit for the treatment of preeclampsia. The ER chaperones are endogenously produced bile salts ursodeoxycholic acid (UDCA, TUDCA). The chaperones have excellent *in vivo* safety profiles and their use has been approved in clinical trials for the treatment of urea-cycle disorders, thalassemia and cystic fibrosis ([@B95]), and they are currently used to treat intrahepatic cholestasis of pregnancy ([@B43]).

STATINS
=======

Preeclampsia has been associated with dyslipidemia, and there is evidence of increased antibodies for oxidized form of LDL in patients with preeclampsia, which is consistent with oxidative stress, and it is analogous to changes described in atherosclerosis ([@B15]). Although preeclampsia is unique to pregnancy, there are many biological and pathological similarities, as well as risk factors (e.g., hypertension, obesity, dyslipidemia, diabetes, etc.) with adult cardiovascular disease. The mechanism underlying both atherosclerosis ([@B51]) and preeclampsia ([@B106]; [@B103]) is initiated by underlying endothelial dysfunction and inflammation, which lead to disease progression and manifestation. Pregnancy is often viewed as a stress test, and preeclampsia an early manifestation of CV disease. In fact, women who develop preeclampsia have a two- to threefold risk of hypertension, ischemic stroke and heart disease in later life ([@B123]; [@B85]), and the risk is further increased with the severity of the disease, and early manifestation before 34 weeks gestation ([@B87]). Given the analogies between the two diseases, some remedies and treatments used to prevent and treat cardiovascular disease have been tested in preeclampsia.

Natural and synthetic statins (or 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase inhibitors) are the most commonly prescribed classes of medication worldwide, used in primary and secondary prevention of cardiovascular mortality and other cardiovascular events through lipid-lowering remedy, as well as many pleiotropic effects, including endothelial protection, antioxidant properties, anti-inflammatory, antithrombotic and proangiogenic effects ([@B31]; [@B48]). The beneficial effects of statins in the treatment of cardiovascular disease have been confirmed by recent meta-analysis of individual data from 90,000 individuals in 14 randomized trials of statin therapy vs. placebo, called the Cholesterol Treatment Trialists' (CTT) Collaboration ([@B8]). The CTT concluded that statin therapy can safely reduce the 5-year incidence of major coronary events, coronary revascularization, and stroke by about one fifth per mmol/L reduction in LDL cholesterol, largely irrespective of the initial lipid profile or other presenting characteristics ([@B8]).

The effect of pravastatin administration in pregnancy has been tested in many rodent models of preeclampsia. Treatment with pravastatin significantly reduced maternal sFlt-1 levels, lowered blood pressure, improved the vascular profile, and prevented kidney injury ([@B5]; [@B32]; [@B42]; [@B74]; [@B109]). In addition, pravastatin also prevented the incidence of intrauterine growth restriction, without any adverse effects on pregnancy. In a mouse model of preeclampsia using placenta-specific lentiviral vector expression of sFlt-1, Kumasawa et al. elegantly demonstrated that pravastatin administration decreased sFlt-1 but importantly increased PlGF, thus restoring the angiogenic balance ([@B74]). Pravastatin effects could be reproduced by administration of PlGF, which reduced sFlt-1 levels, ameliorated hypertension, glomerular endotheliosis, and proteinuria in the mice, suggesting that the beneficial effect of pravastatin on improving preeclampsia-like symptoms is mediated by increasing PlGF levels, which counteracts sFlt-1-mediated effects ([@B74]). In addition, statins also exert protective effects on the endothelium and ameliorate preeclampsia symptoms by increasing the release of vasodilators NO ([@B101]; [@B42]) and CO ([@B33]; [@B88]). Pravastatin treatment of mice destined to develop preeclampsia using sFlt-1 overexpression increased eNOS protein expression in the vasculature ([@B42]), whilst pravastatin improved pregnancy outcome by increasing plasma NO levels in CBAxDBA/2 mice destined to develop recurrent miscarriage and IUGR ([@B101]). Treatment of mice with statins resulted in increased HO-1 activity and increased CO release from tissues, as well as increased levels of plasma antioxidants ([@B88]). Statins also induced the expression of HO-1 and inhibited sFlt-1 secretion in placental explants ([@B33]). These studies provide further evidence of a pleiotropic role of pravastatin in preventing the vascular dysfunction.

Given the encouraging evidence of the beneficial effects of statins on the prevention of cardiovascular disease in humans and of preeclampsia in animal models, the ability of pravastatin to restore angiogenic balance is currently being tested in the first randomized placebo controlled StAmP trial (Statins to ameliorate early onset preeclampsia) in the UK. The aim of the trial is to establish if pravastatin can lead to a significant reduction in circulating antiangiogenic factors and alleviate the severity of early onset preeclampsia. The pleiotropic anti-inflammatory, anti-thrombotic, antioxidant and vascular protective effects suggest that statins might be a good therapeutic option to prevent preeclampsia.

FUTURE DIRECTIONS -- H~2~S DONORS
=================================

Endogenous H~2~S plays an important role in regulating physiological processes such as blood flow, vasodilation, arterial diameter, and leukocyte adhesion ([@B129]). Endogenous production is catalyzed by cystathionine β-synthase (CBS) and cystathionine γ-lyase (CSE). H~2~S is produced in the cardiovascular system by CSE, using cysteine as a substrate. It acts as a vasodilator, being able to hyperpolarize and relax SMCs by opening K~ATP~ channels ([@B138]). Unlike NO and CO, which mediate vasorelaxation largely by cGMP pathway activation, the vasorelaxant effect of H~2~S is independent of cGMP pathway ([@B138]). In addition, NO effects depend largely on the endothelial function integrity, whereas H~2~S is an endothelium-independent vasodilator and exerts its direct effect on SMCs. CSE knockout mice have markedly reduced serum H~2~S levels, which results in pronounced hypertension and diminished vasodilation, providing direct evidence that H~2~S is a potent vasodilator that can influence blood pressure ([@B131]). Similarly, genetic deficiency of CBS leads to homocysteinemia, which is associated with endothelial dysfunction and hypertension ([@B86]). We reported reduced CSE expression in IUGR cases, as well as PE cases that were accompanied by abnormal UA Doppler profiles, and this could be recapitulated by subjecting placental explants to HR. In addition, we demonstrated a potent vasodilatory effect of an H~2~S donor in perfused placentas, capable of K~ATP~ dependent-reduction of placental vascular resistance. Reduced bioavailability of H~2~S may thus be implicated in placental vasoconstriction ([@B25]). In addition to being a potent vasodilator, many animal studies also showed a protective role of H~2~S donors against ischemia-reperfusion injury and inflammation ([@B13], [@B14]; [@B117]). The pro-survival pathways AKT, PKC, and ERK1/2 have been identified as H~2~S targets conferring its anti-apoptotic effects during reperfusion injury ([@B56]; [@B132]). Additionally, H~2~S can promote direct anti-apoptotic signaling during ischemia-reperfusion by activating eNOS and thus inducing NO ([@B132]), and H~2~S promotes DNA binding and transcriptional activation of anti-apoptotic genes regulated by NF-κB ([@B114]). The antioxidant properties of H~2~S can be mediated via two distinct mechanisms; by acting as a direct scavenger of ROS and by up-regulating antioxidant defenses. H~2~S may up-regulate endogenous antioxidants through a nuclear factor E2-related factor-2 (Nrf2; [@B21]). Nrf2 binds the antioxidant responsive element (ARE) found in the promoter region of antioxidant genes, including heme oxygenase-1 (HO-1), thioredoxin, thioredoxin reductase, glutathione reductase, glutathione peroxidase (GPx), glutathione *S*-transferase (GSS), and catalase and is thus an important factor in controlling cardiac cellular susceptibility to reactive oxygen and nitrogen species-induced cytotoxicity ([@B141]). Garlic oil can also promote Nrf-2 activation, further supporting the role for Nrf2 as the mediator of H~2~S-induced antioxidant effects ([@B41]). Additionally, CSE expression appears to be a critical component of the cytoprotective ATF4 transcriptional response; CSE deficiency increases sensitivity to apoptosis induced by ER stressors and homocysteine, indicating the importance of GSH up-regulation through the transsulfuration pathway to promote survival ([@B36]). H~2~S also exerts important proangiogenic effects ([@B20]; [@B128]; [@B12]; [@B54]). H~2~S promotes proliferation, adhesion, migration and tube-like structure formation of endothelial cells *in vitro* via AKT pathway phosphorylation. It also stimulates angiogenesis *in vivo* at physiologically relevant doses ([@B20]). NO-H~2~S cross-talk seems critical in mediating these effects ([@B12]; [@B30]). H~2~S therapy restores blood flow to ischemic tissues in a NO-dependent manner, by stimulating NOS expression and HIF-1α and VEGF expression and activity ([@B12]).

Consistent with these roles of H~2~S, the consumption of garlic is negatively correlated with the progression of CV disease, and causes a lower incidence of hypertension, enhances antioxidants and inhibits platelet aggregation ([@B10]). It has been shown that the biological production of H~2~S from garlic-derived organic polysulfides mediates the major beneficial effects of garlic-rich diets, specifically on CV disease and more broadly on overall health ([@B11]). In animal models of hypoxic pulmonary hypertension, H~2~S could reverse structural remodeling changes in pulmonary vessels of rats exposed to chronic HR ([@B55]). H~2~S therapy also protected against acute myocardial ischemia/reperfusion ([@B21]), and attenuated cardiac dysfunction following heart failure ([@B72]; [@B98]). Recent animal studies have focused on the use of "medical food," i.e., drugs derived from natural sources such as garlic, as a cardioprotective therapy for heart failure. These include diallyl trisulfide (DATS; [@B98]), a long acting H~2~S donor derived from garlic, and sulfur-releasing "medical food" SG-1002 ([@B72]), which is currently in clinical trials. Similar results have been reported in the placental field recently. [@B54] evaluated the therapeutic effect of an H~2~S donor in an animal model of sFlt-induced hypertension. They reported a significant reduction in blood pressure, and proteinuria, as well as concomitant reduction in sFlt-1 levels and increase in free maternal VEGF concentrations in the treated group of animals ([@B54]). [@B127] demonstrated that CSE enzyme inhibition in pregnant mice induced hypertension, increased sFlt-1 and sEng levels, caused placental abnormalities and compromised fetal growth. H~2~S donor therapy reduced the levels of the antiangiogenic factors and restored fetal growth, adding further weight to the evidence that a dysfunctional CSE/H~2~S pathway may contribute to the pathogenesis of preeclampsia ([@B127]), and that H~2~S donor therapy could have beneficial effects on prevention of preeclampsia.

CONCLUDING REMARKS
==================

Therapeutic interventions to treat preeclampsia remain largely experimental and there is no established remedy for the treatment of this multifactorial disease. This review concentrated on the evidence for the therapeutic potential of antioxidants, ER chaperones, NO and H~2~S donors, and statins. Mechanistic effects of these compounds on the signaling pathways involved in the pathophysiology of preeclampsia, are summarized in **Figure [1](#F1){ref-type="fig"}**. Antioxidants, ER chaperones, NO donors, statins and H~2~S donors display pleitropic antioxidant, anti-inflammatory, and pro-angiogenic effects in animal and *in vitro* studies. Encouraging clinical evidence exists for the use of NO donors, and a clinical trial is currently underway testing the effect of statins in treatment of preeclampsia. Although clinical trials on the use of antioxidant vitamins in pregnancy proved largely unsuccessful, the scope for their use still exists given the beneficial cardioprotective effects of antioxidant-rich Mediterranean diet, periconceptual vitamin use and the synergistic effect of vitamin C and [L]{.smallcaps}-arginine. H~2~S recently emerged as a novel therapeutic agent for cardiovascular disease and its effects are being tested.

![**Proposed pathways contributing to the maternal syndrome of preeclampsia and the mechanism of action of antioxidants, ER chaperones, NO, and H~2~S donors and statins**. Deficient conversion of spiral arteries leads to fluctuations in O~2~ concentration and triggers ischemia-reperfusion type injury of the placenta and consequent oxidative stress and ER stress. ROS activate various stress pathways, including proapoptotic p38 and inflammatory NF-κB pathway. These pathways promote increased shedding of microparticles, anti-angionenic factors and inflammatory cytokines, which lead to development of the peripheral maternal symptoms. Antioxidants, ER chaperones, NO and H~2~S donors and statins all display pleitrophic effects, targeting inflammatory, stress, antioxidant pathways, as well as VEGF and NO signaling.](fphar-05-00119-g001){#F1}
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ADMA

:   asymmetric dimethylarginine

AKT

:   serine/threonine-specific protein kinase

ALK1 and ALK5

:   TGF-β receptors type I

ARE

:   antioxidant responsive element

ATF6

:   activating transcription factor 6

CBS

:   cystathionine β-synthase

CO

:   carbon monoxide

CSE

:   cystathionine γ-lyase

CTT

:   cholesterol treatment trialists

CV

:   cardiovascular

DAMPs

:   damage-associated molecular pattern

EDF

:   end diastolic flow

eIF2α

:   eukaryotic initiation factor 2α

eNOS

:   endothelial nitric oxide synthase

ER

:   endoplasmic reticulum

ERK

:   extracellular signal-regulated kinase

ET-1

:   endothelin-1

GPx

:   glutathione peroxidase

GRP78

:   78 kDa glucose-regulated protein, also known as binding immunoglobulin protein (BiP) or heat shock 70 kDa protein 5 (HSPA5)

GSS

:   glutathione S-transferase

H~2~S

:   hydrogen sulfide

HELLP syndrome

:   hemolysis, elevated liver enzymes and low platelets

HO-1

:   heme oxygenase

HIF-1α

:   hypoxia-induced factor

HR

:   hypoxia-reoxygenation

ICAM

:   intercellular adhesion molecule

I/R

:   ischemia-reperfusion

IRE1

:   inositol-requiring enzyme 1

IUGR

:   intrauterine growth restriction

LDL

:   low density lipoprotein

NADPH

:   nicotinamide adenine dinucleotide phosphate

NF-κB

:   nuclear factor kappa-light-chain-enhancer of activated B cells

NO

:   nitric oxide

Nrf2

:   nuclear factor E2-related factor-2

p38 MAPK

:   p38 mitogen-activated protein kinase

PE

:   preeclampsia

PERK

:   PRKR-like ER kinase

PlGF

:   placental growth factor

ROS

:   reactive oxygen species

RUPP

:   reduced uterine perfusion pressure

sEng

:   soluble TGF-β co-receptor endoglin

sFlt1

:   soluble VEGF receptor 1, also referred to as soluble fms-like tyrosine kinase

SGA

:   small for gestational age

SOD

:   superoxide dismutase

StAmP trial

:   Statins to ameliorate early onset preeclampsia

TLR

:   Toll-like receptors

TUDCA

:   Tauroursodeoxycholic acid, bile salt

UDCA

:   ursodeoxycholic acid, bile salt

UPR

:   Unfolded Protein Response

VCAM-1

:   vascular cell adhesion molecule 1

VEGF

:   vascular endothelial growth factor

XBP-1

:   X-box binding protein-1.
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